Zebrafish mutant model reveals novel drug candidates for ADHD
Reykjavik – 3Z. ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the development of non-stimulant based therapeutics is of high importance. In a study published in the journal Neuropsychopharmacology 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics. First, it was shown that when the human ADHD risk gene